Scorpius Holdings Inc. · OTC:SCPX
Scorpius — Heat Biologics — Technical Presentation (June 2015)
5 slides from Scorpius's technical presentation, Jun 15, 2015
Slide 1: Figure 1. Testing synergy between Im PACT and T cell costimulators
Figure 1. Testing synergy between Im PACT and T cell costimulators. (A) Diagram of co-stimulator receptors and ligands on T cells and antigen presenting cells (APC). (B) Schematic of Gp96-Ig Im PACT vaccine. (C) Co-stimulator antibodies analyzed.
Slide 2: Figure 2. OX40 antibody synergizes with gp96-Ig vaccine to produce T cell expansion
Figure 2. OX40 antibody synergizes with gp96-Ig vaccine to produce T cell expansion. Mice transferred with OT-I (EGFP) cells via tail vein injection on day -1, were then vaccinated with Im PACT +/- T cell co-stimulator agonistic antibodies for OX40, ICOS and 4-1BB, and then analyzed by flow cytometr
Slide 3: ‘OTA Total cos:
‘OTA Total cos:
Slide 4: Com PACT generates greater T cell expansion than OX40 antibody
Figure 3 . Com PACT generates greater T cell expansion than OX40 antibody, and is specific to antigen related CD8 cells. (A) Schematic of new vaccine Com PACT. (B) Antigen specific (OT-I/ EGFP) CD8 T cell expansion analyzed by flow cytometry following vaccination and boost by Im PACT +/- OX40(ab) or
Slide 5: Figure 5. Com PACT increases survival in murine CT26 tumor model system
Figure 5. Com PACT increases survival in murine CT26 tumor model system. (A) Diagram of experimental setup showing tumor inoculation of 5x10 5 CT26 cells on day 0 and vaccination days 6 and 11 (1x10 6 cells and 100 ì g of antibody for appropriate treatments). (B) Overall survival of mice inoculated
Heat Biologics — Technical Presentation (June 2015) on 6ix